Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

STAT3 maintains skin barrier integrity by modulating SPINK5 and KLK5 expression in keratinocytes

ABSTRACT: We elucidated the potential role of STAT3 in the skin barrier and its effect on kallikrein-related peptidase 5 (KLK5) and serine protease inhibitor Kazal-type 5 (SPINK5) expression using a mouse model with keratinocyte-specific ablation of STAT3.

ORGANISM(S): Mus musculus

PROVIDER: GSE166140 | GEO | 2021/02/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

STAT3 maintains skin barrier integrity by modulating SPINK5 and KLK5 expression in keratinocytes

Project description:STAT3 maintains skin barrier integrity by modulating SPINK5 and KLK5 expression in keratinocytes

| PRJNA699446 | ENA

High expression of KLK5 enhances radiation resistance of cervical cancer

Project description:Studies have demonstrated the correlation between kallikrein-related peptidase 5 (KLK5) and cervical cancer prognosis, but studies on the correlation between KLK5 and radiation resistance are rare. Therefore, we aimed to investigate the role of high KLK5 expression in improving radiation resistance in cervical cancer and the underlying mechanisms. Samples from 29 patients with cervical cancer who received definitive radiotherapy without surgical treatment and other antineoplastic treatments (2014–2016) were analyzed. The patients were divided into the radiotherapy-sensitive (RS) group (18 patients without local recurrence and distant metastasis within 3 years after initial treatment) and the radiotherapy-resistant (RR) group (11 patients with uncontrolled conditions with radiotherapy, local recurrence, or distant metastasis within 3 years after initial treatment). We used high-throughput gene sequencing to detect radiosensitivity-related factors. We found that the expression of KLK5 in the RR group was higher than that in the RS group, and this result was associated with poor outcomes after radiotherapy as patients developed distant metastasis and showed recurrence at 2–3 years of follow-up. Besides, a high KLK5 expression enhances radiation resistance, indicating that, with further research, KLK5 may be used to develop novel molecular target-specific modulators for anti-cervical cancer therapy, acting as a prognostic agent in personalized precision medicine for cancer.

2024-11-24 | GSE189721 | GEO

Human keratinocyte transcriptome response to KLK5 and KLK7

Project description:To determine how KLK5 and KLK7 can impact keratinocyte responses we treated human primary keratinocytes with recombinant KLK5 and KLK7 for 4 hours.

2023-03-01 | GSE205531 | GEO

Comparative analyses of Netherton syndrome patients and Spink5 conditional knock-out mice define disease-relevant pathways

Project description:Netherton syndrome (NS) is a rare skin disease caused by loss-of-function mutations in the serine peptidase inhibitor Kazal type 5 (SPINK5) gene. Disease severity and the lack of efficacious treatments call for a better understanding of NS mechanisms. Here we describe a viable, Spink5 conditional knock-out (cKO) mouse model, allowing to study NS progression. Using comparative transcriptomics and proteomics, we determine a disease molecular profile conserved in mouse models and NS patients. Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation of proteases, IL-17, IL-36, IL-20 family cytokines. Furthermore, we show that systemic inflammation in Spink5 cKO mice is associated with thymic atrophy and is driven by innate immunity and IL-17/IL-22 signaling. By comparing skin transcriptomes and proteomes, we uncovered several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines. Our study thus provides a conserved molecular framework for NS disease, adding new insights into its mechanisms and therapeutic targets.

2023-02-02 | MSV000091184 | MassIVE

Therapeutic effect of anti-KLK5 and KLK7 in a mouse model of atopic dermatitis

Project description:To investigate the effect of blocking the activity of KLK5 and KLK7 in the skin in a model of atopic dermatitis, we treated mice inhibitory antibodies against KLK5 and KLK7.

2023-03-01 | GSE205530 | GEO

Effect of KLK5 knockdown in PC9 lung cancer cells

Project description:Response of PC9 cells to infection with NT (control) lentivirus or one of two different KLK5 knockdown lentiviruses.

2018-04-06 | GSE112783 | GEO

STAT3 contributes to cisplatin resistance, modulating EMT markers and the mTOR signaling in lung adenocarcinoma cells .

Project description:Lung cancer is the second leading cause of cancer death worldwide and is strongly associated with cisplatin resistance. The transcription factor STAT3 is constitutively activated in cancer cells and coordinates critical cellular processes as survival, self-renewal, and inflammation. In several types of cancer, STAT3 controls the development, immunogenicity, and malignant behavior of tumor cells while dictates the responsiveness to radio- and chemotherapy. It is known that STAT3 phosphorylation on Ser727 by mTOR is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. In this study, using a proteomic label-based approach, we reveal important targets and signaling pathways increased and decreased in cisplatin-resistant A549 lung adenocarcinoma cells.

2022-02-17 | PXD025778 | Pride

Human keratinocyte transcriptome response to KLK5 and KLK7

Project description:Human keratinocyte transcriptome response to KLK5 and KLK7

| PRJNA846288 | ENA

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Project description:Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer. Despite our knowledge of STAT3’s importance to cancer, scientists and doctors have not developed a drug that targets it and that patients can take to treat their cancer more effectively than treatments that are now available. Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs. In this application, Tvardi is proposing to further develop TTI-101 for treatment of solid tumors for which the prognosis is dismal. The investigators will determine how safe it is when administered to patients with cancer, determine whether an adequate dose can be administered to patients with cancer that will block STAT3 in their cancer, and determine whether treatment with TTI-101 leads to reduced growth of their cancer.

| 2247646 | ecrin-mdr-crc

Effect of KLK5 knockdown in PC9 lung cancer cells

Project description:Effect of KLK5 knockdown in PC9 lung cancer cells

| PRJNA448952 | ENA